Effect of Short-Term Administration of Cromakalim on Renal Hemodynamics and Eicosanoid Excretion in Essential Hypertension
Open Access
- 1 September 1991
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 4 (9) , 740-744
- https://doi.org/10.1093/ajh/4.9.740
Abstract
Cromakalim, a novel potassium channel-activating drug, was administered for a 3-day period in eight untreated hospitalized patients with established hypertension. The fixed and single dose of 1.5 mg/day produced a significant reduction in systolic and diastolic blood pressure with a small increase in heart rate. Glomerular filtration rate was unchanged and effective renal plasma flow was slightly increased with a concomittant small decrease in filtration fraction and in renal vascular resistance. No significant change was observed in urinary prostaglandin (PG)E2, PGF2α, and thromboxane B2, while 6-keto-PGF1α a (the stable metabolite of prostacyclin) rose from 189 ± 6 to 368 ± 115 ng/day. The renal excretion of 6-keto-PGF1α a correlates with the modification observed in renal plasma flow, suggesting a compensatory role for prostacylin in preserving renal hemodynamics during antihypertensive therapy with cromakalim. Am J Hypertens 1991;4:740–744Keywords
This publication has 0 references indexed in Scilit: